Xencor

company

About

Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.

  • 101 - 250

Details

Last Funding Type
Series E
Last Funding Money Raised
$15M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 1997
Number Of Employee
101 - 250
Operating Status
Active

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy.

The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$15M
Xencor has raised a total of $15M in funding over 2 rounds. Their latest funding was raised on Oct 25, 2007 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 25, 2007 Series E $15M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Xencor is funded by 1 investors. Novo Nordisk are the most recent investors.
Investor Name Lead Investor Funding Round
Novo Nordisk Series E